Subscribe to RSS
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/s-0041-1731777
The Importance of Appropriate Dosing of Nonvitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation
![](https://www.thieme-connect.de/media/10.1055-s-00033990/202103/lookinside/thumbnails/10-1055-s-0041-1731777_200090-1.jpg)
Abstract
Preventing thromboembolic events, while minimizing bleeding risks, remains challenging when managing patients with atrial fibrillation (AF). Several factors contribute to current dosing patterns of nonvitamin K antagonist oral anticoagulants (NOACs), including patient characteristics, comorbidities, and physician judgment. Application of NOAC doses inconsistent with the drug labels may cause patients to receive either subtherapeutic (increasing stroke risk) or supratherapeutic (increasing bleeding risk) anticoagulant levels. In clinical practice, under- or over-dosing of NOACs in patients with AF is not uncommon. This analysis of prospective and retrospective registry and database studies on NOAC use in patients with AF (with at least 250 patients in each treatment arm) showed that under-dosing may be associated with reduced effectiveness for stroke prevention, with similar or even increased bleeding than with the standard dose. This may reflect underlying conditions and patient factors that increase bleeding despite NOAC dose reduction. Such factors could drive the observed overuse of reduced NOAC dosages, often making the prescription of reduced-dose NOAC an intentional label deviation. In contrast, over-dosing more likely occurs accidentally; instead of providing benefits, it may be associated with worse safety outcomes than the standard dose, including increased bleeding risk and higher all-cause mortality rates. This review summarizes the main findings on NOAC doses usually prescribed to patients with AF in clinical practice.
Note
The authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
Publication History
Received: 03 November 2020
Accepted: 22 April 2021
Article published online:
23 August 2021
© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22 (08) 983-988
- 2 Kirchhof P, Benussi S, Kotecha D. et al; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37 (38) 2893-2962
- 3 Kirchhof P, Ammentorp B, Darius H. et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events--European Registry in Atrial Fibrillation (PREFER in AF). Europace 2014; 16 (01) 6-14
- 4 Plitt A, Bansilal S. The nonvitamin K antagonist oral anticoagulants and atrial fibrillation: challenges and considerations. J Atr Fibrillation 2017; 9 (05) 1547
- 5 Ruff CT, Giugliano RP, Braunwald E. et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 2015; 385 (9984): 2288-2295
- 6 Steffel J, Verhamme P, Potpara TS. et al; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39 (16) 1330-1393
- 7 Eliquis ® [Summary of Product Characteristics]. Uxbridge: Bristol Myers Squibb, Pfizer Inc; 25 May 2021
- 8 Pradaxa ® [Summary of Product Characteristics]. Ingelheim am Rhein: Boehringer Ingelheim International GmbH; 22 June 2021
- 9 Lixiana ® [Summary of Product Characteristics]. Munich: Daiichi Sankyo Europe GmbH; 23 April 2021
- 10 Xarelto ® [Summary of Product Characteristics]. Berlin: Bayer AG; 02 February 2021
- 11 Connolly SJ, Ezekowitz MD, Yusuf S. et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
- 12 Giugliano RP, Ruff CT, Braunwald E. et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369 (22) 2093-2104
- 13 Gong IY, Kim RB. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol 2013; 29 (07) S24-S33
- 14 Granger CB, Alexander JH, McMurray JJ. et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
- 15 Patel MR, Mahaffey KW, Garg J. et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
- 16 Reilly PA, Lehr T, Haertter S. et al; RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014; 63 (04) 321-328
- 17 Ruff CT, Giugliano RP, Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383 (9921): 955-962
- 18 Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol 2017; 69 (23) 2779-2790
- 19 Yu HT, Yang PS, Jang E. et al. Label adherence of direct oral anticoagulants dosing and clinical outcomes in patients with atrial fibrillation. J Am Heart Assoc 2020; 9 (12) e014177
- 20 García Rodríguez LA, Martín-Pérez M, Vora P. et al. Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK. BMJ Open 2019; 9 (09) e031341
- 21 Cho MS, Yun JE, Park JJ. et al. Pattern and impact of off-label underdosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation who are indicated for standard dosing. Am J Cardiol 2020; 125 (09) 1332-1338
- 22 Nabauer M, Gerth A, Limbourg T. et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 2009; 11 (04) 423-434
- 23 Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GYH, Larsen TB. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2017; 356: j510
- 24 Steinberg BA, Shrader P, Thomas L. et al; ORBIT-AF Investigators and Patients. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am Coll Cardiol 2016; 68 (24) 2597-2604
- 25 Lee KN, Choi JI, Boo KY. et al. Effectiveness and safety of off-label dosing of non-vitamin K antagonist anticoagulant for atrial fibrillation in Asian patients. Sci Rep 2020; 10 (01) 1801
- 26 Dillinger JG, Aleil B, Cheggour S. et al. Dosing issues with non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: why we should not underdose our patients. Arch Cardiovasc Dis 2018; 111 (02) 85-94
- 27 Dobesh PP, Fanikos J. Reducing the risk of stroke in patients with nonvalvular atrial fibrillation with direct oral anticoagulants. Is one of these not like the others?. J Atr Fibrillation 2016; 9 (02) 1481
- 28 Suárez Fernández C, Formiga F, Camafort M. et al; Grupo de trabajo de Riesgo vascular de la SEMI. Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach. BMC Cardiovasc Disord 2015; 15: 143
- 29 Heidbuchel H, Berti D, Campos M. et al. Implementation of non-vitamin K antagonist oral anticoagulants in daily practice: the need for comprehensive education for professionals and patients. Thromb J 2015; 13: 22
- 30 Hijazi Z, Hohnloser SH, Oldgren J. et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014; 129 (09) 961-970
- 31 Bohula EA, Giugliano RP, Ruff CT. et al. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial. Circulation 2016; 134 (01) 24-36
- 32 Hohnloser SH, Hijazi Z, Thomas L. et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012; 33 (22) 2821-2830
- 33 Fox KAA, Piccini JP, Wojdyla D. et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32 (19) 2387-2394
- 34 Gupta M, Singh N, Tsigoulis M. et al. Underuse of full dose Factor Xa inhibition in atrial fibrillation: insight from the SPRINT-AF registry. J Am Coll Cardiol 2015; 65: A348
- 35 Weitz JI, Eikelboom JW. Appropriate apixaban dosing: prescribers take note. JAMA Cardiol 2016; 1 (06) 635-636
- 36 Staerk L, Gerds TA, Lip GYH. et al. Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study. J Intern Med 2018; 283 (01) 45-55
- 37 Graham DJ, Reichman ME, Wernecke M. et al. Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med 2016; 176 (11) 1662-1671
- 38 Hernandez I, Zhang Y. Comparing stroke and bleeding with rivaroxaban and dabigatran in atrial fibrillation: analysis of the US Medicare part D data. Am J Cardiovasc Drugs 2017; 17 (01) 37-47
- 39 Pradaxa ® [Prescribing Information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; July 2020
- 40 Helmert S, Marten S, Mizera H. et al. Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry. J Thromb Thrombolysis 2017; 44 (02) 169-178
- 41 Beyer-Westendorf J, Ebertz F, Förster K. et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost 2015; 113 (06) 1247-1257
- 42 Hecker J, Marten S, Keller L. et al. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost 2016; 115 (05) 939-949
- 43 Kakkar AK, Mueller I, Bassand JP. et al; GARFIELD Registry Investigators. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One 2013; 8 (05) e63479
- 44 Ding M, Fratiglioni L, Johnell K, Fastbom J, Ljungdahl M, Qiu C. Atrial fibrillation and use of antithrombotic medications in older people: a population-based study. Int J Cardiol 2017; 249: 173-178
- 45 de Almeida JPHCL, Martinho AS, Girão A. et al. Novel anticoagulants in an older and frail population with atrial fibrillation: the effect of inappropriate dosing on clinical outcomes. Eur Geriatr Med 2020; 11 (05) 813-820
- 46 Steinberg BA, Shrader MA, Thomas L. et al. Association of inappropriate dosing of non-vitamin K oral anticoagulants and risk of adverse events: results from the ORBIT-AF II registry. Paper presented at: European Society of Cardiology congress; Rome, Italy, August 27–31, 2016, Abstract 2954
- 47 Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost 2016; 14 (06) 1308-1313
- 48 Güler E, Babur Güler G, Demir GG, Hatipoğlu S. A review of the fixed dose use of new oral anticoagulants in obese patients: Is it really enough?. Anatol J Cardiol 2015; 15 (12) 1020-1029
- 49 Proietti M, Guiducci E, Cheli P, Lip GYH. Is there an obesity paradox for outcomes in atrial fibrillation? A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant trials. Stroke 2017; 48 (04) 857-866
- 50 Tittl L, Endig S, Marten S, Reitter A, Beyer-Westendorf I, Beyer-Westendorf J. Impact of BMI on clinical outcomes of NOAC therapy in daily care - results of the prospective Dresden NOAC Registry (NCT01588119). Int J Cardiol 2018; 262: 85-91
- 51 Lucijanic M, Jurin I, Jurin H. et al. Patients with higher body mass index treated with direct / novel oral anticoagulants (DOAC / NOAC) for atrial fibrillation experience worse clinical outcomes. Int J Cardiol 2020; 301: 90-95
- 52 Boriani G, Ruff CT, Kuder JF. et al. Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. Eur Heart J 2019; 40 (19) 1541-1550
- 53 Costa OS, Beyer-Westendorf J, Ashton V. et al. Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data. Curr Med Res Opin 2020; 36 (07) 1081-1088
- 54 Kushnir M, Choi Y, Eisenberg R. et al. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data. Lancet Haematol 2019; 6 (07) e359-e365
- 55 Martin AC, Thomas W, Mahir Z. et al. Direct oral anticoagulant concentrations in obese and high body weight patients: a cohort study. Thromb Haemost 2021; 121 (02) 224-233
- 56 Netley J, Howard K, Wilson W. Effects of body mass index on the safety and effectiveness of direct oral anticoagulants: a retrospective review. J Thromb Thrombolysis 2019; 48 (03) 359-365
- 57 Perales IJ, San Agustin K, DeAngelo J, Campbell AM. Rivaroxaban versus warfarin for stroke prevention and venous thromboembolism treatment in extreme obesity and high body weight. Ann Pharmacother 2020; 54 (04) 344-350
- 58 Piran S, Traquair H, Chan N, Bhagirath V, Schulman S. Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: a retrospective study. Res Pract Thromb Haemost 2018; 2 (04) 684-688
- 59 Spyropoulos AC, Ashton V, Chen YW, Wu B, Peterson ED. Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: comparative effectiveness, safety, and costs. Thromb Res 2019; 182: 159-166
- 60 Nielsen PB, Lane DA, Rasmussen LH, Lip GYH, Larsen TB. Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. Clin Res Cardiol 2015; 104 (05) 418-429
- 61 Okumura K, Akao M, Yoshida T. et al; ELDERCARE-AF Committees and Investigators. Low-dose edoxaban in very elderly patients with atrial fibrillation. N Engl J Med 2020; 383 (18) 1735-1745